OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Finkelstein on the Significance of the 2024 ACRO Summit

March 26th 2024

Steven E. Finkelstein, MD, DABR, FACRO, on advancing radiation oncology and updates from the 2024 ACRO Summit.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Dr Spratt on Metastasis-Directed Therapy and Hypofractionation in Prostate Cancer

March 26th 2024

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL

March 25th 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma

March 25th 2024

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Dr Spratt on the Use of Radiation in Low– and High-Risk Prostate Cancer

March 22nd 2024

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

March 22nd 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Dr Xu on Treatment Decision-Making in RCC

March 22nd 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Dr Koo on Treating Various Stages of Prostate Cancer

March 22nd 2024

Philip J. Koo, MD, discusses the treatment of patients with prostate cancer throughout the different stages of their disease.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer

March 22nd 2024

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Dr D’Amico on Advancements in High-Risk Prostate Cancer Diagnosis and Management

March 22nd 2024

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

Dr Kuerer on Advancements in Neoadjuvant Systemic Therapies in Breast Cancer

March 22nd 2024

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Dr Lee on Head and Neck Cancer Updates from the 2024 ACRO Summit

March 21st 2024

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Dr Masters on the 2024 ACRO Summit

March 21st 2024

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.

Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer

March 21st 2024

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian Cancer

March 21st 2024

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL

March 20th 2024

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Hernandez-Ilizaliturri on the Potential Advantages of Iopofosine I 131 in Waldenström Macroglobulinemia

March 20th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.